Synvista Therapeutics Statistics
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
SYNI has 2.59 million shares outstanding.
| Current Share Class | 2.59M |
| Shares Outstanding | 2.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.01
| Current Ratio | 2.01 |
| Quick Ratio | 1.91 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,591.12 |
Financial Efficiency
Return on equity (ROE) is -102.91% and return on invested capital (ROIC) is -64.68%.
| Return on Equity (ROE) | -102.91% |
| Return on Assets (ROA) | -50.59% |
| Return on Invested Capital (ROIC) | -64.68% |
| Return on Capital Employed (ROCE) | -240.88% |
| Revenue Per Employee | 6,081 |
| Profits Per Employee | -2.20M |
| Employee Count | 9 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | -1.41 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 41.93 |
| Average Volume (20 Days) | 883 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SYNI had revenue of 54,729 and -19.80 million in losses. Loss per share was -7.66.
| Revenue | 54,729 |
| Gross Profit | 54,729 |
| Operating Income | -11.03M |
| Pretax Income | -10.96M |
| Net Income | -19.80M |
| EBITDA | -11.01M |
| EBIT | -11.03M |
| Loss Per Share | -7.66 |
Balance Sheet
The company has 7.96 million in cash and n/a in debt, giving a net cash position of 7.96 million or 3.08 per share.
| Cash & Cash Equivalents | 7.96M |
| Total Debt | n/a |
| Net Cash | 7.96M |
| Net Cash Per Share | 3.08 |
| Equity (Book Value) | 4.58M |
| Book Value Per Share | 1.73 |
| Working Capital | 4.23M |
Cash Flow
In the last 12 months, operating cash flow was -9.32 million and capital expenditures -21,350, giving a free cash flow of -9.34 million.
| Operating Cash Flow | -9.32M |
| Capital Expenditures | -21,350 |
| Free Cash Flow | -9.34M |
| FCF Per Share | -3.61 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -20,147.39% |
| Pretax Margin | -20,034.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SYNI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.08% |
| Shareholder Yield | n/a |
| Earnings Yield | -660,149,533.33% |
| FCF Yield | -311,353,166.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 25, 2007. It was a reverse split with a ratio of 0.02.
| Last Split Date | Jul 25, 2007 |
| Split Type | Reverse |
| Split Ratio | 0.02 |
Scores
SYNI has an Altman Z-Score of -47.27 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -47.27 |
| Piotroski F-Score | 1 |